"The U.S. Food and Drug Administration today expanded the approved use of Xgeva (denosumab) to treat adults and some adolescents with giant cell tumor of the bone (GCTB), a rare and usually non-cancerous tumor.
GCTB generally occurs in a"...
Patients receiving OptiMARK™ Injection should be instructed before injection to:
- Inform their physician or health care provider if they are pregnant or breast feeding (see PRECAUTIONS, Pregnancy Category C and Nursing Mothers).
- Inform their physician or health care provider if they have a history of renal and/or liver disease, anemia, hemoglobinopathies, or diseases that affect red blood cells.
- Inform their physician or health care provider if they have a history of asthma or allergic respiratory disorders, seizures, or heart disease.
- Inform their physician or health care provider of all medications they may be taking.
- Inform their physician if they have recently received a GBCA.
GBCAs increase the risk for NSF among patients with impaired elimination of the drugs. To counsel patients at risk for NSF:
- Describe the clinical manifestations of NSF
- Describe procedures to screen for the detection of renal impairment
Instruct the patients to contact their physician if they develop signs or symptoms of NSF following OptiMARK™ administration, such as burning, itching, swelling, scaling, hardening and tightening of the skin; red or dark patches on the skin; stiffness in joints with trouble moving, bending or straightening the arms, hands, legs or feet; pain in the hip bones or ribs; or muscle weakness.
Last reviewed on RxList: 9/9/2013
This monograph has been modified to include the generic and brand name in many instances.
Additional OptiMARK Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.